The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Abstract
Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which "brorphine" made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug class was developed and investigated by the pharmaceutical industry in the 1950s and 1960s but never reached clinical use because the balance between their therapeutic and toxic effects was less favourable than that of morphine [3]”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [3]
In the citing paper
“While the NSO market is currently largely dominated by benzimidazole opioids (Ujváry et al., 2021)”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
In the citing paper
“Notably, brorphine appeared on recreational drug markets around the globe from 2019 onwards (Krotulski et al., 2020b; Ujváry et al., 2021; Vandeputte et al., 2022a; Verougstraete et al., 2020) and was also identified in (postmortem) toxicology samples (Krotulski et al., 2020a; Verougstraete et al., 2020; Vohra et al., 2021).”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
Citations
Cites
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Stein, C. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093100 · Cited by 525
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Properties of Opiate-Receptor Binding in Rat Brain
Pert, C. B., & Snyder, S. H. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.8.2243 · Cited by 436
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Kumar, K. K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., KATO, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 423
HUGHES, J., KOSTERLITZ, H. W., & LESLIE, F. M. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07373.x · Cited by 403
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
Tyers, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 342
Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
Morgan, M. M., & Christie, M. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01335.x · Cited by 270
Imidazole and Benzimidazole Synthesis
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-303190-7.x5012-2 · Cited by 239
Research works printed but not linked: 36
- Gulland J. M., 1925, Mem. Proc. Manchester Lit. Philos. Soc., 69, 79
- European Monitoring Centre for Drugs and Drug Addiction, 2020, European Drug Report 2020: Trends and Developments
- United Nations Office on Drugs and Crime, 2021, World Drug Report 2020
- United Nations Office on Drugs and Crime. growing complexity of the opioid crisis. Global SMART Update Vol. 24, UNODC, Vienna, 2020. https://www.unodc.org/documents/scientific/Global_SMART-2020-Vol_24_web.pdf (accessed Feb 24, 2021).
- Grimmett M. R., 2002, Hetarenes and Related Ring Systems. Five-Membered Hetarenes with Two Nitrogen or Phosphorus Atoms, Science of Synthesis, 12, 529
- StarDrop , version 6.6 software, Optibrium Ltd., Cambridge, U.K.
- Sparatore F., 1968, Farmaco, Ed. Sci., 23, 344
- Bucha M., 2018, Indian J. Heterocycl. Chem., 28, 321
- European Monitoring Centre for Drugs and Drug Addiction, 2020, Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No. 1920/2006 (as amended)
- Gonthier, V. Une toute nouvelle drogue inquiete les autorites. Le Journal du Quebec. 1 Février, 2020. https://journaldequebec.com/2020/02/01/une-toute-nouvelle-drogue-inquiete-les-autorites (accessed Feb 24, 2021).
- Sorokin V. I., 1999, J. Clandestine Lab. Invest. Chem. Assoc., 9, 20
- Brittain R. T., 1973, Br. J. Pharmacol., 49, 158P
- Jacobson A. E., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 490
- Aceto M. D., 1994, Problems of Drug Dependence, 1993, NIDA Research Monograph Series 140, 103
- Aceto M. D., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 513
- Eddy N. B., 1959, Chem. Ind., 47, 1462
- Fraser H. F., 1960, Minutes of the Twenty-First Meeting, 11–12 January, 1960, Committee on Drug Addiction and Narcotics, 35
- 1961, World Health Organization Technical Report Series No. 211, 1
- Butelman E. R., 1993, J. Pharmacol. Exp. Ther., 264, 145
- Emmerson P. J., 1994, J. Pharmacol. Exp. Ther., 271, 1630
- Toll L., 1998, NIDA Research Monograph Series 178, 440
- Rothman R. B., 1985, Mol. Pharmacol., 27, 399
- Lecolier S., 1967, Chim. Ther., 2, 16
- Lénárd K., 1962, Acta Chim. Acad. Sci. Hung., 34, 439
- Janssen P. A. J., 1971, Arzneim.-Forsch., 21, 862
- Li Q., 1984, Acta Pharm. Sin., 19, 124
- Department of Justice., 2021, Fed. Regist., 86, 11862
- Holliday E. R., 1949, J. Pharm. Pharmacol., 1, 734
- Ramsh S. M., 2011, Stud. Hist. Biol., 3, 36
- Feitelson B. N., 1958, J. Chem. Soc., 2426
- Brandenberger H., 1974, Dtsch. Lebensmitt. Rundsch., 70, 31
- Anonymous., 1987, BKA - Wöchentlicher Lagebericht, 87, 9
- Sorokin V. I., 1999, Microgram, 32, 239
- Anonymous., 2003, Microgram Bull., 36, 275
- deStevens G., 1965, Analgetics, 405
- Archer S., 1965, Progr. Drug Res., 8, 261
Cited by
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Treatment of overdose in the synthetic opioid era
Skolnick, P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108019 · Cited by 126
Krotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91
Montanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86
Metadata
- Authors
- Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R.
- Affiliations
- iKem BT, H-1033 Budapest, Hungary
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- European Monitoring Centre for Drugs and Drug Addiction, 1249-289 Lisbon, Portugal
- Corresponding author
- Ujváry, István
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-24
- Volume
- 12
- Issue
- 7
- Pages
- 1072-1092
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3137216449
- Cited by
- 141
- References
- 121
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 27 · 2023: 20 · 2022: 21 · 2021: 8
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Monitoring Centre for Drugs and Drug Addiction (CT.20.SAS.0017.1.0)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- etonitazene, isotonitazene, mu-opioid receptor agonists, synthetic opioids, benzimidazolone, analgesics, drug regulation, addiction liability, pharmacotoxicology, Ciba, drug development history
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Europe, Humans, Morphine, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles. https://app.cochat.ai/papers/10.1021/acschemneuro.1c00037
- The paper
- Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021). DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.1c00037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.